Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078029" target="_blank" >RIV/65269705:_____/23:00078029 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00130968 RIV/61989592:15110/23:73619682 RIV/00098892:_____/23:10157887 RIV/00209805:_____/23:00079258

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6010" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cam4.6010" target="_blank" >10.1002/cam4.6010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

Popis výsledku v původním jazyce

Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra-adrenal location, they are called paragangliomas (PGLs) and arise from sympathetic and parasympathetic ganglia, particularly of the para-aortic location. Up to 25% of PCCs/PGLs are associated with inherited genetic disorders. The majority of PCCs/PGLs exhibit indolent behavior. However, according to their affiliation to molecular clusters based on underlying genetic aberrations, their tumorigenesis, location, clinical symptomatology, and potential to metastasize are heterogenous. Thus, PCCs/PGLs are often associated with diagnostic difficulties. In recent years, extensive research revealed a broad genetic background and multiple signaling pathways leading to tumor development. Along with this, the diagnostic and therapeutic options were also expanded. In this review, we focus on the current knowledge and recent advancements in the diagnosis and treatment of PCCs/PGLs with respect to the underlying gene alterations while also discussing future perspectives in this field.

Název v anglickém jazyce

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

Popis výsledku anglicky

Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra-adrenal location, they are called paragangliomas (PGLs) and arise from sympathetic and parasympathetic ganglia, particularly of the para-aortic location. Up to 25% of PCCs/PGLs are associated with inherited genetic disorders. The majority of PCCs/PGLs exhibit indolent behavior. However, according to their affiliation to molecular clusters based on underlying genetic aberrations, their tumorigenesis, location, clinical symptomatology, and potential to metastasize are heterogenous. Thus, PCCs/PGLs are often associated with diagnostic difficulties. In recent years, extensive research revealed a broad genetic background and multiple signaling pathways leading to tumor development. Along with this, the diagnostic and therapeutic options were also expanded. In this review, we focus on the current knowledge and recent advancements in the diagnosis and treatment of PCCs/PGLs with respect to the underlying gene alterations while also discussing future perspectives in this field.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Medicine

ISSN

2045-7634

e-ISSN

2045-7634

Svazek periodika

12

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

16

Strana od-do

13942-13957

Kód UT WoS článku

000981618600001

EID výsledku v databázi Scopus

2-s2.0-85158078654